Investor Presentaiton

Investor presentation First three months of 2017 Slide 90 Long-acting obesity compounds in phase 1 development may have complimentary modes of action Compound Key features of compounds in phase 1 development for obesity G530S- Glucagon analogue NN9838 Amylin analogue NN9747 - PYY analogue NN9499 - FGF21 analogue NN9277 - GG- co-agonist - NN9423 Tri- agonist 1706 Admin Once-daily sc injection in combination with liraglutide Once-daily sc injection Once-daily sc injection Once-daily sc injection Once-weekly sc injection Once-daily sc injection Stimulation of Mode of energy action satiety expenditure and Reduced food intake, primarily to be mediated by amylin receptors Reduced food intake via selective stimulation of the Y2 receptor FGF21-induced weight loss presumed to be driven by energy expenditure Phase 1 trial status Expected Expected Expected completion 2017 completion 2018 completion 2019 PK: pharmacokinetic; SC: Subcutaneous changing diabetes Stimulation of Stimulation of energy energy expenditure and expenditure and satiety satiety Expected Expected Expected completion 2018 completion 2018 completion 2017 novo nordisk

View entire presentation